Infliximab biosimilar (AXXO)

英夫利西单抗生物类似药 (AXXO)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameInfliximab biosimilar (AXXO)
Drug Alias NameInfliximab follow-on biologic (AXXO)英利昔单抗生物仿制药 (AXXO)infliximab follow-on biologic
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsAutoimmune DiseasesCrohn Disease
Global Approved IndicationsAutoimmune DiseasesCrohn Disease
Approved Indications in ChinaN/A
Original Approved Country/TerritoryRussian Federation
Original Approved Date2013/01/01
Country/TerritoryRussian Federation
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAxxo
China Registration ClassN/A

Develop Information

Active CompaniesAxxo
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesCrohn Disease
Inactive IndicationsN/A

Other Information

ATC CodeL04AB02
Related LinksN/A